diabetic retinopathy market is projected n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Diabetic Retinopathy Market is expected to be $ 2.6 Billion by 2025 PowerPoint Presentation
Download Presentation
Diabetic Retinopathy Market is expected to be $ 2.6 Billion by 2025

Loading in 2 Seconds...

play fullscreen
1 / 2

Diabetic Retinopathy Market is expected to be $ 2.6 Billion by 2025 - PowerPoint PPT Presentation


  • 12 Views
  • Uploaded on

A research study titled, “Diabetic Retinopathy Market by Type, Treatment, and End User - Global Industry Analysis and Forecast to 2025” published by Crystal Market Research, states that the diabetic retinopathy market is projected to be around $2.6 billion by 2025.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Diabetic Retinopathy Market is expected to be $ 2.6 Billion by 2025' - RobinHood90


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
diabetic retinopathy market is projected

Diabetic Retinopathy Market is projected to be around $ 2.6 Billion by

2025 - Crystal Market research

A research study titled, “Diabetic Retinopathy Market by Type, Treatment, and End User -

Global Industry Analysis and Forecast to 2025” published by Crystal Market Research, states

that the diabetic retinopathy market is projected to be around $2.6 billion by 2025.

For more information, click on the below link @

https://www.crystalmarketresearch.com/report/diabetic-retinopathy-market

Report Overview:

Diabetic retinopathy (DR) is a condition that occurs in individuals suffering from diabetes. It is a

severe sight-threatening problem of diabetes which progressively damages the light-sensitive

lining at the back of the eye i.e. retina. This condition occurs when blood vessels leak blood.

Therefore, the retinal tissue swells leading to blurred vision. If DR is not treated on time, it can

cause blindness. According to a study conducted by American Diabetes Association, 415 million

people worldwide suffered from diabetes and diabetes related complications as of 2015, and this

number is expected to reach 642 million by 2040.

Diabetic macular edema market is expected to witness high growth during forecast period. This

can be attributed to number of factors such as rise in prevalence of diabetic retinopathy, growing

aging population and the changing lifestyle. Anti-VEGF treatment segment accounted for the

largest share due to more usage of these medicines for quicker recovery of patients. However,

laser surgery segment is expected to witness high growth rate during the forecast period.

1 | P a g e

regional outlook north america dominated

Regional Outlook:

North America dominated the global diabetic retinopathy market in 2016. This can be attributed

to number of factors such as increasing prevalence of diabetes, high adoption of advanced

products, and favorable reimbursement policies. Asia-Pacific is expected to witness high growth

rate, due to high patient population, increasing healthcare spending, and increased focus of

international players on emerging markets owing to growing preference for advanced healthcare

facilities and rising disposable income of people.

Major Market Players:

Diabetic retinopathy market is highly competitive in nature with the presence of large number of

players such as Bayer AG, F. Hoffmann-La Roche, Allergan plc, Alimera Sciences, Novartis

International AG, Pfizer, Regeneron Pharmaceuticals Inc., Ampio Pharmaceuticals., Abbott

Laboratories, and Valeant Pharmaceutical.

Key Findings of the Research Study:

U.S. dominated the North America market in 2016, due to high market penetration of drugs such

as Avastinand Eylea.

Europe occupied the second largest share of the global market in 2016. This can be attributed to

rise in diabetic population, high adoption of technologically advanced products, and rise in

demand for early screening techniques.

Asia-Pacific is expected to witness high growth rate during the forecast period due to large

diabetic population base and increasing awareness about diabetes and availability of treatment

options.

Purchase the report @ https://www.crystalmarketresearch.com/checkout/HC0622

About Crystal Market Research:

Crystal offers one stop solution for market research, business intelligence, and consulting

services to help clients make more informed decisions. It provides both syndicated as well as

customized research studies for its customers spread across the globe. The company offers

market intelligence reports across a broad range of industries including healthcare, chemicals &

materials, technology, automotive, and energy.

Contact Us:

Judy

304 South Jones Blvd, Suite 1896,

Las Vegas NV 89107, United States.

Toll Free: +1-888-213-4282

Website: http://www.crystalmarketresearch.com

For More Discounts Offers Email at sales @ sales@crystalmarketresearch.com

2 | P a g e